Moderna shares dip after soaring on mRNA cancer vaccine trial success

Moderna (MRNA) shares slipped 12% in pre-market trading on Thursday after the company and partner Merck announced that their personalized mRNA cancer vaccine, intismeran, achieved its primary goal in a late-stage Phase 3 trial. The study showed a significant reduction in melanoma recurrence when the vaccine was combined with Merck's immunotherapy Keytruda, compared with Keytruda alone, extending the time patients remained free of disease.

Dr. Ezekiel Emanuel described the results as "a home run, maybe even a grand slam" during a Yahoo Finance interview. Analysts offered varied perspectives. Jefferies analyst Tycho Peterson said the data provide an important proof point for mRNA applications beyond COVID-19 and could benefit the broader bioprocessing ecosystem. Bank of America analyst Alec Stranahan called the outcome a "watershed moment" for Moderna, suggesting it may help the company diversify away from infectious-disease focus, though he noted uncertainties around label expansions and market uptake. Citigroup analyst Geoff Meacham cautioned that while meeting disease-free survival without new safety signals is encouraging, full validation of Moderna's oncology platform will depend on additional data and evidence of efficacy across other tumor types.